Integra Lifesciences Holdings Corp
IART12.360USD
+0.050+0.41%
Market hours （ET）Quotes delayed by 15 min
963.10MMarket Cap
LossP/E TTM
More Details of Integra Lifesciences Holdings Corp Company
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
Company Info
Ticker SymbolIART
Company nameIntegra Lifesciences Holdings Corp
IPO dateAug 16, 1995
CEOMs. Mojdeh Poul
Number of employees4396
Security typeOrdinary Share
Fiscal year-endAug 16
Address1100 Campus Road
CityPRINCETON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code08540
Phone16092750500
Websitehttps://www.integralife.com/
Ticker SymbolIART
IPO dateAug 16, 1995
CEOMs. Mojdeh Poul
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.79M
+1.82%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Mr. Harvinder Singh
Mr. Harvinder Singh
Executive Vice President, President - International Business
Executive Vice President, President - International Business
13.25K
+1024.00%
Ms. Mojdeh Poul
Ms. Mojdeh Poul
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Shaundra D. Clay
Ms. Shaundra D. Clay
Independent Director
Independent Director
--
--
Mr. Chris Ward
Mr. Chris Ward
IR Contact Officer
IR Contact Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.79M
+1.82%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Neurosurgery
190.91M
49.89%
Wound Reconstruction and Care
74.78M
19.54%
Instruments
50.95M
13.31%
ENT
38.80M
10.14%
Private Label
27.21M
7.11%
By RegionUSD
Name
Revenue
Proportion
United States
282.22M
73.75%
Asia Pacific
45.10M
11.79%
Europe
35.33M
9.23%
Rest of World
20.00M
5.23%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Neurosurgery
190.91M
49.89%
Wound Reconstruction and Care
74.78M
19.54%
Instruments
50.95M
13.31%
ENT
38.80M
10.14%
Private Label
27.21M
7.11%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.52%
TRU ST Partnership, L.P.
10.93%
The Vanguard Group, Inc.
9.59%
Rubric Capital Management LP
9.44%
Fuller & Thaler Asset Management Inc.
5.03%
Other
52.49%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.52%
TRU ST Partnership, L.P.
10.93%
The Vanguard Group, Inc.
9.59%
Rubric Capital Management LP
9.44%
Fuller & Thaler Asset Management Inc.
5.03%
Other
52.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.95%
Investment Advisor/Hedge Fund
39.09%
Hedge Fund
15.00%
Corporation
10.96%
Individual Investor
3.45%
Research Firm
1.90%
Pension Fund
1.10%
Sovereign Wealth Fund
0.62%
Bank and Trust
0.45%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
598
89.03M
114.56%
-18.85M
2025Q1
635
87.01M
111.97%
-18.30M
2024Q4
636
81.93M
106.10%
-20.27M
2024Q3
638
82.93M
106.93%
-12.58M
2024Q2
628
84.82M
107.92%
-1.75M
2024Q1
613
79.36M
101.18%
-3.69M
2023Q4
597
79.81M
101.26%
-5.74M
2023Q3
592
81.88M
100.31%
-3.94M
2023Q2
587
82.30M
100.29%
-6.57M
2023Q1
579
85.87M
104.63%
-5.43M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
9.75M
12.55%
-341.75K
-3.38%
Mar 31, 2025
TRU ST Partnership, L.P.
8.52M
10.96%
--
--
Feb 28, 2025
The Vanguard Group, Inc.
7.47M
9.61%
-66.65K
-0.88%
Mar 31, 2025
Rubric Capital Management LP
4.64M
5.98%
+2.03M
+77.35%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
3.92M
5.05%
-9.76K
-0.25%
Mar 31, 2025
Invesco Advisers, Inc.
3.13M
4.02%
+1.36M
+77.42%
Mar 31, 2025
Wellington Management Company, LLP
2.77M
3.56%
+259.99K
+10.37%
Mar 31, 2025
State Street Global Advisors (US)
2.75M
3.54%
-105.48K
-3.70%
Mar 31, 2025
Boston Management and Research
2.74M
3.53%
--
--
Mar 31, 2025
AllianceBernstein L.P.
2.71M
3.48%
+128.04K
+4.97%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
1.98%
SPDR S&P Health Care Equipment ETF
1.75%
ROBO Global Healthcare Technology & Innovation ETF
1.08%
Invesco S&P SmallCap Health Care ETF
0.59%
Invesco NASDAQ Future Gen 200 ETF
0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
0.2%
Royce Quant Small-Cap Quality Value ETF
0.15%
iShares S&P Small-Cap 600 Value ETF
0.13%
SPDR S&P 600 Small Cap Value ETF
0.13%
Vanguard US Value Factor ETF
0.12%
View more
iShares Neuroscience and Healthcare ETF
Proportion1.98%
SPDR S&P Health Care Equipment ETF
Proportion1.75%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.08%
Invesco S&P SmallCap Health Care ETF
Proportion0.59%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.2%
Royce Quant Small-Cap Quality Value ETF
Proportion0.15%
iShares S&P Small-Cap 600 Value ETF
Proportion0.13%
SPDR S&P 600 Small Cap Value ETF
Proportion0.13%
Vanguard US Value Factor ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
